Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors

High expression levels of human epidermal growth factor receptor 2 (HER2) have been associated with poor prognosis in patients with pancreatic adenocarcinoma (PDAC). However, HER2-targeting immunotherapies have been unsuccessful to date. Here we increase the breadth, potency, and duration of anti-PD...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosewell Shaw, Amanda, Porter, Caroline E., Yip, Tiffany, Mah, Way-Champ, McKenna, Mary K., Dysthe, Matthew, Jung, Youngrock, Parihar, Robin, Brenner, Malcolm K., Suzuki, Masataka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979740/
https://www.ncbi.nlm.nih.gov/pubmed/33742099
http://dx.doi.org/10.1038/s42003-021-01914-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979740/
https://www.ncbi.nlm.nih.gov/pubmed/33742099
http://dx.doi.org/10.1038/s42003-021-01914-8

Ejemplares similares